| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802355601011 | 235560101 | NARAMIG F.C.TAB 2,5MG/TAB BTx2 (BLISTER) | 4.53 | 4.75 | 6.55 |
| 05/2018 | 2802355601028 | 235560102 | NARAMIG F.C.TAB 2,5MG/TAB BTx4 (BLISTER) | 07.04 | 7.38 | 10.17 |
For the acute treatment of migraine attacks with or without aura in adults.
Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.
Symptoms of overdose include light-headedness, loss of coordination, tension in the neck, and tiredness.
Well absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours. The rate of absorption is slower during a migraine attack.
5-8 hours
* 170 L
* 6.6 mL/min/kg